Valuation: Celcuity Inc.

Market Cap 430.8Cr 378.37Cr 351.88Cr 322.89Cr 606.69Cr 41TCr 616.05Cr 4.18TCr 1.63TCr 20TCr 1.62TCr 1.58TCr 71TCr P/E 2026 *
-21x
P/E 2027 * -176x
Enterprise Value 430.8Cr 378.37Cr 351.88Cr 322.89Cr 606.69Cr 41TCr 616.05Cr 4.18TCr 1.63TCr 20TCr 1.62TCr 1.58TCr 71TCr EV / Sales 2026 *
111x
EV / Sales 2027 * 11x
Free-Float
89.97%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Celcuity Inc.

1 day-5.13%
1 week-4.25%
Current month-19.12%
1 month-12.20%
3 months-30.08%
6 months-25.78%
Current year-15.16%
1 week 84.62
Extreme 84.62
92.66
1 month 84.62
Extreme 84.62
117.21
Current year 82.55
Extreme 82.5536
151.02
1 year 13.59
Extreme 13.59
151.02
3 years 7.58
Extreme 7.575
151.02
5 years 4.81
Extreme 4.81
151.02
10 years 4.03
Extreme 4.03
151.02
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 64 01/01/2012
Chief Executive Officer 64 01/01/2012
Director of Finance/CFO 59 01/07/2017
Director TitleAgeSince
Chairman 64 01/01/2012
Director/Board Member 64 01/01/2012
Director/Board Member 67 01/02/2014
Date Insider Type Main position Quantity % Market Cap.
14/07/26
Baker Bros. Advisors LP
SellCompany -31,00,000 6.6996%
10/06/26 Don

Director

-28,096 0.0607%
10/06/26 Don

Director

-25,006 0.0540%
Change 5-day change 1-year change 3-year change Capi.($)
-5.13%-4.25%+502.28%+730.42% 430.8Cr
-1.92%-1.57%+48.70%+84.37% 5.59TCr
+0.93%+6.97%+62.83%+67.97% 5.67TCr
-2.29%-1.39%-21.26%-15.72% 2.33TCr
-0.77%-1.37%+3.20%+422.17% 2.33TCr
-0.36%-0.56%+36.00%-3.93% 2.05TCr
-1.34%+0.51%+25.02%-30.27% 1.78TCr
-1.44%-1.63%+37.07%+589.93% 1.59TCr
-1.30%-9.92%+160.67%+284.37% 1.46TCr
+0.24%-0.34%+24.43%+180.19% 1.4TCr
Average -1.34%+0.43%+87.89%+230.95% 2.46TCr
Weighted average by Cap. -0.88%+1.44%+50.73%+148.69%

Financials

2026 *2027 *
Net sales 3.89Cr 3.41Cr 3.17Cr 2.91Cr 5.47Cr 374.28Cr 5.56Cr 38Cr 15Cr 184.01Cr 15Cr 14Cr 636.22Cr 39Cr 35Cr 32Cr 29Cr 55Cr 3.79TCr 56Cr 381.57Cr 149.08Cr 1.86TCr 147.68Cr 144.5Cr 6.44TCr
Net income -22Cr -19Cr -18Cr -17Cr -31Cr -2.13TCr -32Cr -214.47Cr -84Cr -1.05TCr -83Cr -81Cr -3.62TCr -3.42Cr -3.01Cr -2.8Cr -2.57Cr -4.82Cr -329.75Cr -4.9Cr -33Cr -13Cr -162.11Cr -13Cr -13Cr -560.52Cr
Net Debt - -
Logo Celcuity Inc.
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a kinase inhibitor of phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), mechanistic target of rapamycin (mTOR) pathway that binds to all class I PI3K isoforms and the mTOR complexes, mTORC1 and mTORC2. A Phase III clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) (HR+/HER2-) advanced breast cancer (ABC) has completed enrollment and reported detailed results for cohort 1, patients with PIK3CA wild-type (WT) tumors, and has completed enrollment of cohort 2, patients with PIK3CA mutant-type (MT) tumors.
Employees
155
Date Price Change Volume
24/26/24 $84.65 -4.18% 3,44,665
23/26/23 $88.34 -2.00% 17,51,907
22/26/22 $90.14 -1.69% 7,92,947
21/26/21 $91.69 +4.21% 18,55,686
20/26/20 $87.99 -0.44% 10,53,678
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
88.34USD
Average target price
163.45USD
Spread / Average Target
+85.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CELC Stock